Donald S. Middleton

965 citations

45 papers · 625 indexed · h-index 16

Organic Chemistry top 5%
- Synthesis of β-Lactam Compounds 5
- Synthesis and Catalytic Reactions 4
- Synthetic Organic Chemistry Methods 4
Virology top 10%
- HIV Research and Treatment 4
Toxicology top 10%
Pharmacology
- Pharmacogenetics and Drug Metabolism 4
Infectious Diseases
- HIV/AIDS drug development and treatment 10
Molecular Biology
- Biochemical and Molecular Research 6
- Chemical Synthesis and Analysis 5

Co-authors: Scott E. Denmark Nigel S. Simpkins Atli Thorarensen N.K. Terrett A. J. Boulton Jeremy Robertson Barry Jones A. Mackenzie
Cited by: Organic Chemistry Virology Toxicology
Journals: Journal of the American Chemical Society (1 paper)Journal of Medicinal Chemistry (3 papers)The Journal of Organic Chemistry (3 papers)
Partner nations: United Kingdom United States Canada

In The Last Decade

Donald S. Middleton

45 papers receiving 593 citations

Peers

Countries citing papers authored by Donald S. Middleton

Since Specialization

Citations

This map shows the geographic impact of Donald S. Middleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald S. Middleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald S. Middleton more than expected).

Fields of papers citing papers by Donald S. Middleton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald S. Middleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald S. Middleton. The network helps show where Donald S. Middleton may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Donald S. Middleton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Donald S. Middleton Line = papers co-authored together Donald S. Middleton links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Non-benzimidazole containing inhibitors of respiratory syncytial virus Bioorganic & Medicinal Chemistry Letters ·David C. Pryde,Thien-Duc Tran,Iain Gardner,Helen Bright,Paul A. Stupple,Sébastien R. G. Galan,Liam Alsop,Lesa Watson,Donald S. Middleton,Satish Dayal,Michelle Y. Platts,Edward J. Murray,Tanya Parkinson,Robert O. Webster	2012	7
2	The design and discovery of novel amide CCR5 antagonists Bioorganic & Medicinal Chemistry Letters ·David C. Pryde,Martin Corless,David R. Fenwick,Helen J. Mason,Blanda C. Stammen,Peter T. Stephenson,David A. Ellis,David Bachelor,David W. Gordon,Chris Barber,Anthony Wood,Donald S. Middleton,David C. Blakemore,Gemma C. Parsons,Rachel L. Eastwood,Michelle Y. Platts,Keith Statham,Kerry A. Paradowski,Catherine Burt,Wolfgang Klute	2009	16
3	Discovery of a small molecule inhibitor through interference with the gp120–CD4 interaction Bioorganic & Medicinal Chemistry Letters ·D. H. Williams,Fiona M. Adam,David R. Fenwick,Juin Fok‐Seang,Iain Gardner,Duncan A. Hay,Rawal Jaiessh,Donald S. Middleton,Charles E. Mowbray,Tanya Parkinson,Manos Perros,Christopher Pickford,Michelle Y. Platts,Amy Randall,Daniel Siddle,Peter T. Stephenson,Thien-Duc Tran,Hannah Vuong	2009	8
4	6 Cytochrome P450 Metabolism and Inhibition: Analysis for Drug Discovery Progress in medicinal chemistry ·Barry Jones,Donald S. Middleton,Kuresh Youdim	2009	7
5	1-Amido-1-phenyl-3-piperidinylbutanes — CCR5 antagonists for the treatment of HIV. Part 1 Bioorganic & Medicinal Chemistry Letters ·Chris Barber,David C. Blakemore,Jean‐Yves Chiva,Rachel L. Eastwood,Donald S. Middleton,Kerry A. Paradowski	2009	12
6	1-Amido-1-phenyl-3-piperidinylbutanes – CCR5 antagonists for the treatment of HIV: Part 2 Bioorganic & Medicinal Chemistry Letters ·Chris Barber,David C. Blakemore,Jean‐Yves Chiva,Rachel L. Eastwood,Donald S. Middleton,Kerry A. Paradowski	2009	17
7	Design and optimisation of potent gp120-CD4 inhibitors Bioorganic & Medicinal Chemistry Letters ·Thien-Duc Tran,Fiona M. Adam,Frederick Calo,David R. Fenwick,Juin Fok‐Seang,Iain Gardner,Duncan A. Hay,Manos Perros,Jaiessh Rawal,Donald S. Middleton,Tanya Parkinson,Christopher Pickford,Michelle Y. Platts,Amy Randall,Peter T. Stephenson,Hannah Vuong,D. H. Williams	2009	8
8	Designing rapid onset selective serotonin re-uptake inhibitors. 2: Structure–activity relationships of substituted (aryl)benzylamines Bioorganic & Medicinal Chemistry Letters ·Donald S. Middleton,Mark D. Andrews,Paul A. Glossop,Geoffrey E. Gymer,David Hepworth,Alan S. Jessiman,Patrick S. Johnson,Malcolm MacKenny,Michael J. Pitcher,Tony Rooker,Alan Stobie,Kim Tang,Paul Morgan	2008	8
9	Optimization of 5‐Aryloxyimidazole Non‐Nucleoside Reverse Transcriptase Inhibitors ChemMedChem ·Lyn H. Jones,Gill Allan,Romuald Corbau,Duncan A. Hay,Donald S. Middleton,Charles E. Mowbray,Sandra D. Newman,Manos Perros,Amy Randall,Hannah Vuong,Rob Webster,Mike Westby,David J. Williams	2008	8
10	Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: Structure–activity relationships of (thioalkyl)phenoxy benzylamines Bioorganic & Medicinal Chemistry Letters ·Donald S. Middleton,Mark D. Andrews,Paul A. Glossop,Geoffrey E. Gymer,David Hepworth,Alan S. Jessiman,Patrick S. Johnson,Malcolm MacKenny,Alan Stobie,Kim Tang,Paul Morgan,Barry Jones	2008	8
11	Synthesis of Enantiomerically Pure 4-Substituted Riboses Synlett ·David C. Pryde,Adrian Maddaford,Thierry Guyot,David Leese,Rebecca Glen,J. Roger Hart,Xiurong Zhang,Ray Fisher,Donald S. Middleton,C.L. Doherty,Nicholas C. Smith,Scott C. Sutton	2007	2
12	Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder Bioorganic & Medicinal Chemistry ·David C. Pryde,Andrew S. Cook,Denise J. Burring,Lyn H. Jones,Stephanie Foll,Michelle Y. Platts,Vivienne Sanderson,Martin Corless,Alan Stobie,Donald S. Middleton,Laura Foster,Laura Barker,Piet van der Graaf,Peter Stacey,Christopher Kohl,Sara Coggon,Kevin Beaumont	2006	16
13	Highly potent and selective zwitterionic agonists of the δ-opioid receptor. Part 1 Bioorganic & Medicinal Chemistry Letters ·Donald S. Middleton,Graham N. Maw,Clare Challenger,Alan S. Jessiman,Patrick S. Johnson,William A. Million,Carly L. Nichols,Jenny Price,Michael A. Trevethick	2005	10
14	Structure–activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)-5-{2-[3-(substituted)-1-azetidinyl]-ethyl}-2-piperidones. Part 2: Improving oral absorption Bioorganic & Medicinal Chemistry Letters ·Donald S. Middleton,A. Mackenzie,Sandra D. Newman,Martin Corless,Andrew N. Warren,Allan P. Marchington,Barry Jones	2005	6
15	Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure–activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine Bioorganic & Medicinal Chemistry Letters ·Donald S. Middleton,Mark D. Andrews,Paul A. Glossop,Geoffrey E. Gymer,Alan S. Jessiman,Patrick S. Johnson,Malcolm MacKenny,Michael J. Pitcher,Tony Rooker,Alan Stobie,Kim Tang,Paul Morgan	2005	10
16	4-Amino-2-(aryl)-butylbenzamides and Their conformationally constrained analogues. Potent antagonists of the human neurokinin-2 (NK2) receptor Bioorganic & Medicinal Chemistry Letters ·A. Mackenzie,Allan P. Marchington,Donald S. Middleton,Sandra D. Newman,Christopher N. Selway,N.K. Terrett	2003	8
17	ChemInform Abstract: Tandem Inter [4 + 2]/Intra [3 + 2] Cycloadditions. Part 17. The Spiro Mode. Efficient and Highly Selective Synthesis of Azapropellanes. ChemInform ·Scott E. Denmark,Donald S. Middleton	1998	1
18	The tandem cycloaddition chemistry of nitroalkenes Pure and Applied Chemistry ·Scott E. Denmark,Mark E. Schnute,A. Thorarensen,Donald S. Middleton,Andreas Stolle	1994	9
19	Total synthesis of (±)-fredericamycin A. Use of radical spirocyclization Journal of the Chemical Society Chemical Communications ·Derrick L. J. Clive,Yong Tao,Ahmad Khodabocus,Yongjin Wu,A. G. ANGOH,Sharon M. Bennett,Christopher N. Boddy,Luc Bordeleau,Dorit Kellner,G. I. Kleiner,Donald S. Middleton,Christopher J. Nichols,Scott R. Richardson,Peter G. Vernon	1992	17
20	Regioselective Oxidation of Polyalkoxy Naphthalenes: Formation of Naphthoquinones by Ammonium Cerium(IV) Nitrate Oxidation of Methoxymethyl Ethers Israel Journal of Chemistry ·Derrick L. J. Clive,Donald S. Middleton	1991	5

About Donald S. Middleton

Donald S. Middleton is a scholar working on Organic Chemistry, Virology and Pharmacology, having authored 45 papers that have together received 625 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (10 papers), Biochemical and Molecular Research (6 papers), Synthesis of β-Lactam Compounds (5 papers), Chemical Synthesis and Analysis (5 papers), Synthesis and Catalytic Reactions (4 papers), Pharmacogenetics and Drug Metabolism (4 papers), HIV Research and Treatment (4 papers) and Synthetic Organic Chemistry Methods (4 papers). The work is most often cited by research in Organic Chemistry (443 citations), Virology (68 citations) and Toxicology (26 citations). Donald S. Middleton has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Scott E. Denmark, Nigel S. Simpkins, Atli Thorarensen, N.K. Terrett, A. J. Boulton, Jeremy Robertson, Barry Jones, A. Mackenzie, Michael J. Begley and Derrick L. J. Clive. Their work appears in journals such as Journal of the American Chemical Society, Journal of Medicinal Chemistry and The Journal of Organic Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact